Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited announced a change in the director’s interest notice related to Dr. Silviu Itescu. The notice disclosed the acquisition of 2,688,154 options, bringing the total options held to 13,341,558, following shareholder approval at the 2024 AGM. This change in director’s interest reflects Mesoblast’s ongoing corporate activities and governance practices, potentially affecting stakeholder perceptions regarding executive alignment with company goals.
More about Mesoblast Limited
Mesoblast Limited is a company operating in the biopharmaceutical industry, primarily focused on the development of cellular medicines. The company targets a range of diseases and conditions using its proprietary technology in regenerative medicine.
YTD Price Performance: 13.64%
Average Trading Volume: 96,460
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.83B
Learn more about MSB stock on TipRanks’ Stock Analysis page.
